Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)

Flavia Salvi, Stefano Luminari, Alessandra Tucci, Stefania Massidda, Anna Marina Liberati, Caterina Stelitano, Manuela Zanni, Alessandro Re, Riccardo Centurioni, Roberto Freilone, Gerardo Musuraca, Luca Nassi, Caterina Patti, Annalisa Arcari, Monica Tani, Alessandro Pulsoni, Vincenzo Pavone, Stefano Volpetti, Annalisa Peli, Andrea EvangelistaMichele Spina, Marco Ladetto, Francesco Merli

Research output: Contribution to journalArticlepeer-review

Abstract

This phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of elderly or cardiopathic patients with HL. Stage I–IIA and IIB–IV patients were treated with three courses of MBVD plus radiotherapy, or six courses of MBVD, respectively, plus radiotherapy limited to bulky or residual disease areas. The primary endpoints were CR rate and the rate of cardiac events. Forty-seven patients were enrolled. Median age was 75 years, 13 had stage I–II disease. Overall, CR was achieved by 36 patients (77%, 95% CI: 62–88), 100% and 68% in stage I–II and III–IV, respectively. With a median follow-up of 40 months (IQR: 36–45). Three-year overall survival (OS) and progression-free survival (PFS) were 70% and 43%, respectively. Cardiac events grades 3–5 were reported in two patients. In conclusion, MBVD’s activity and safety profile was comparable to historical ABVD data.

Original languageEnglish
Pages (from-to)2890-2898
Number of pages9
JournalLeukemia and Lymphoma
Volume60
Issue number12
DOIs
Publication statusPublished - Dec 1 2019

Keywords

  • cardiotoxicity
  • co-morbidity
  • elderly
  • Hodgkin lymphoma
  • liposomal doxorubicin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)'. Together they form a unique fingerprint.

Cite this